Search research articles
Contact Us
Filters
Showing results (61-70 of 86) with videos related to
Page
of 9
Sort By:
Melanoma Research
|
November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin, David Minor, Sandra D'Angelo, et al.
The Lancet. Oncology
|
April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial
Ana Oaknin, Kathleen Moore, Tim Meyer, et al.
JACC. Cardiooncology
|
January 13, 2023
Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis
Alexi Vasbinder, YeeAnn Chen, Adrien Procureur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204
Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
The Lancet. Oncology
|
August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
Tony Reid, Bryan Oronsky, Jan Scicinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma
Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes, et al.
The New England Journal of Medicine
|
August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
The New England Journal of Medicine
|
January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 86) with videos related to
Sort By:
Page
of 9
Melanoma Research
|
November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin, David Minor, Sandra D'Angelo, et al.
The Lancet. Oncology
|
April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial
Ana Oaknin, Kathleen Moore, Tim Meyer, et al.
JACC. Cardiooncology
|
January 13, 2023
Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis
Alexi Vasbinder, YeeAnn Chen, Adrien Procureur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204
Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
The Lancet. Oncology
|
August 23, 2015
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
Tony Reid, Bryan Oronsky, Jan Scicinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma
Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes, et al.
The New England Journal of Medicine
|
August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
The New England Journal of Medicine
|
January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
Page
of 9